Relay Therapeutics stock: Bank of America maintains a USD 25.00 target for Relay Therapeutics stock

Published on 10/24/2026 at 02:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 0.35 million versus USD 0.96 million expected. Relay Therapeutics stock had a USD 25.92 consensus target on October 20, 2026.

Targets and quarterly evidence

Bank of America maintained a USD 25.00 target on October 23, 2026.
Second-quarter revenue was USD 0.35 million versus USD 0.96 million expected.
Relay Therapeutics had a USD 4.0 billion market capitalization on October 23, 2026.

RLAY, US75943R1023, Illustration mit AI erstellt.

Relay Therapeutics (US75943R1023) reported second-quarter revenue of USD 0.35 million versus USD 0.96 million expected, while its adjusted loss per share was USD 0.41 against USD 0.39 consensus, according to MarketBeat on October 20, 2026. The latest signal came from Bank of America, which maintained a Buy rating and a USD 25.00 target in a report dated October 23, 2026, as reported by Business Insider.

Three dated signals

Relay Therapeutics last released quarterly results on August 6, 2026, reporting an adjusted loss per share of USD 0.41 and revenue of USD 0.35 million, according to MarketBeat. On October 6, 2026, Chief Financial Officer Thomas Catinazzo sold 17,717 shares for USD 329,359.03, the same outlet reported. On October 23, 2026, Bank of America kept its Buy rating and USD 25.00 target, according to Business Insider.

What does the target imply?

The analyst backdrop remains numerically constructive but not uniform. MarketBeat cited a USD 25.92 average target and a Moderate Buy consensus on October 20, 2026, while Bank of America retained a lower USD 25.00 target three days later. The same MarketBeat report listed two Strong Buy ratings, 10 Buy ratings, one Hold rating and one Sell rating. That spread matters because Relay remains a clinical-stage biotechnology company whose valuation depends heavily on development progress rather than product revenue.

Cash and valuation frame

Relay Therapeutics reported USD 121.2 million in cash at June 30, 2026, while operating cash flow for the second quarter was negative USD 54.1 million. Revenue of USD 0.35 million in the quarter therefore stood beside a substantially larger research and development effort, a familiar profile for a clinical-stage drug developer. The company describes its Dynamo platform as a combination of computational and experimental technologies for precision medicines.

Market value and next signals

Relay Therapeutics had a market capitalization of USD 4.0 billion on October 23, 2026. Its 52-week range was USD 5.95 to USD 21.27 on that date, placing the market value below the yearly high while leaving the analyst consensus above the latest US quote. The next material catalyst is the company's clinical and financial reporting cadence, with the second-quarter figures and October analyst update providing the latest dated reference points.